{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-050815","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2026-07-30T12:03:54+00:00","discovered_at":"2026-07-30T12:05:00.362431+00:00","generated_at":"2026-07-30T12:05:04.862890+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vericel Q2 revenue up 22% to $77.5M, raises FY guidance, authorizes $200M buyback","bullets":["Q2 total revenue $77.5M (+22% YoY); MACI $65.5M (+23%); Burn Care $12.0M (+22%).","Net income $2.2M ($0.04 diluted EPS) vs net loss $0.6M in Q2 2025; adjusted EBITDA margin 19%.","FY 2026 revenue guidance raised to $330-340M (from $326-336M); MACI to $284-290M; Burn Care to $46-50M.","Board authorized $200M share repurchase program; company has $227M cash and no debt.","Free cash flow $14.3M in Q2; record MACI biopsies and implants; UK MHRA submission for MACI."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-050815","json":"https://secwatch.observer/filing/0001628280-26-050815.json","markdown":"https://secwatch.observer/filing/0001628280-26-050815.md","text":"https://secwatch.observer/filing/0001628280-26-050815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828026050815/0001628280-26-050815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828026050815/vcel-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T12:05:04.862890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}